Brief: EXACT Therapeutics AS Gets Positive Safety Review For 60 Μl/Kg Dose In Phase 2 ENACT Trial
26/06/2026 07:48
BRIEF-EXACT Therapeutics AS Gets Positive Safety Review For 60 Μl/Kg Dose In Phase 2 ENACT Trial June 26 (Reuters) - Exact Therapeutics AS EXTX.OL:
EXACT THERAPEUTICS AS - TRIAL MONITORING COMMITTEE ISSUES POSITIVE SAFETY READ-OUT FOR 60 ΜL/KG DOSE IN PHASE 2 ENACT TRIAL
EXACT THERAPEUTICS AS - SAFETY READ-OUT TRIGGERS OPENING OF FULL ENROLMENT AT ALL SITES
EXACT THERAPEUTICS AS - INTERIM EFFICACY READ-OUT EXPECTED AROUND END-2026
Source text: ID:nObirn87ka
Further company coverage: EXTX.OL
(((( Reuters.Briefs@thomsonreuters.com ;));))
Recent news on Exact Therapeutics AS
See all newsBrief: EXACT Therapeutics AS Gets Positive Safety Review For 60 Μl/Kg Dose In Phase 2 ENACT Trial
Brief: Exact Therapeutics Introduces New Long-Term Incentive Program
Brief: Exact Therapeutics H1 Operating Loss Widens To NOK 45.9 Million
Brief: Exact Therapeutics Announces Grant Of Core Patent In U.S.
Brief: Exact Therapeutics Announces Final Positive Data From Phase 1 Trial